Study of FP-1039 in Subjects With Endometrial Cancers

Summary

An open-label, non-randomized, single arm study to assess the safety, tolerability, and pharmacokinetics of FP-1039 given by weekly intravenous (IV) administrations in advanced endometrial cancer patients with FGFR2-specific mutations. FP-1039 will be dosed weekly starting at a dose of up to 16 mg/kg.

Timeline

Start

2011-01

Primary completion

2012-06

Completion

2012-12

Drugs

Indications

No indication recorded.